{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:02:26Z","timestamp":1767844946503,"version":"3.49.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T00:00:00Z","timestamp":1525651200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["Fellowships, 310977\/2014-2 to CP-d-S, 310797\/2015-2 to AM and grant 404400\/2012-4 to CP-d-S, AM"],"award-info":[{"award-number":["Fellowships, 310977\/2014-2 to CP-d-S, 310797\/2015-2 to AM and grant 404400\/2012-4 to CP-d-S, AM"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["grant E-26-201.583\/2014, E-26-102957\/2011, and E-26\/111.682\/2013 to CP-d-S and fellowships E-26\/102415\/2010 and E-26\/201747\/2015 to DN"],"award-info":[{"award-number":["grant E-26-201.583\/2014, E-26-102957\/2011, and E-26\/111.682\/2013 to CP-d-S and fellowships E-26\/102415\/2010 and E-26\/201747\/2015 to DN"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00967","type":"journal-article","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T07:18:17Z","timestamp":1525677497000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis"],"prefix":"10.3389","volume":"9","author":[{"given":"Dirlei","family":"Nico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Martins Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Maria Motta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fellipe","family":"Soares dos Santos Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celio Geraldo","family":"Freire-de-Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Freire-de-Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Melo","family":"de Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Maria Blanco Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Morrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarisa Beatriz","family":"Palatnik-de-Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/bmj.325.7357.176","article-title":"The world\u2019s most neglected diseases. Ignored by the pharmaceutical industry and by public-private partnerships","volume":"325","author":"Yamey","year":"2002","journal-title":"BMJ"},{"key":"B2","first-page":"28","article-title":"Control of the leishmaniasis","year":"2010"},{"key":"B3","unstructured":""},{"key":"B4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/1756-3305-4-197","article-title":"One health: the global challenge of epidemic and endemic leishmaniasis","volume":"4","author":"Palatnik-de-Sousa","year":"2011","journal-title":"Parasit Vectors"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0002-9440(10)64199-5","article-title":"A role for tumor necrosis factor-\u03b1 in remodeling the splenic marginal zone during Leishmania donovani infection","volume":"161","author":"Engwerda","year":"2002","journal-title":"Am J Pathol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.4049\/jimmunol.158.8.3813","article-title":"Destruction of follicular dendritic cells during chronic visceral leishmaniasis","volume":"158","author":"Smelt","year":"1997","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.pt.2004.08.009","article-title":"Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis","volume":"20","author":"Engwerda","year":"2004","journal-title":"Trends Parasitol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ni861","article-title":"Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis","volume":"3","author":"Ato","year":"2002","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1126\/science.286.5447.2098","article-title":"Chemokines and cell migration in secondary lymphoid organs","volume":"286","author":"Cyster","year":"1999","journal-title":"Science"},{"key":"B13","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.4049\/jimmunol.162.7.3859","article-title":"The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells","volume":"162","author":"Kellermann","year":"1999","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.provac.2014.07.010","article-title":"Vaccination with nucleoside hidrolase (NH36) of L. (L.) donovani or its C-terminal portion (F3) in formulation with saponin prevents the increase of the proportions of spleen dendritic cells in murine experimental visceral leishmaniasis","volume":"8","author":"Nico","year":"2014","journal-title":"Procedia Vaccinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e866","DOI":"10.1371\/journal.pntd.0000866","article-title":"Adaptive immunity against Leishmania nucleoside hydrolase maps its C-terminal domain as the target of the CD4+ T cell-driven protective response","volume":"4","author":"Nico","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1128\/IAI.73.2.812-819.2005","article-title":"Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis","volume":"73","author":"Aguilar-Be","year":"2005","journal-title":"Infect Immun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.provac.2012.04.009","article-title":"The Leishmune\u00ae\u2019s nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis","volume":"6","author":"Borja-Cabrera","year":"2012","journal-title":"Procedia Vaccinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1016\/j.vaccine.2006.03.005","article-title":"Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of L. donovani","volume":"24","author":"Gamboa-Le\u00f3n","year":"2006","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fimmu.2017.00227","article-title":"Leishmania donovani nucleoside hydrolase (NH36) domains induce T-cell cytokine responses in human visceral leishmaniasis","volume":"8","author":"Barbosa Santos","year":"2017","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3389\/fimmu.2017.00750","article-title":"F1 domain of the Leishmania donovani nucleoside hydrolase promotes a Th1 response in Leishmania infantum cured patients and in asymptomatic individuals living in an endemic area of leishmaniasis","volume":"8","author":"Carrillo","year":"2017","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fimmu.2017.00100","article-title":"A chimera containing CD4+ and CD8+ T-cell epitopes of the Leishmania donovani-nucleoside hydrolase NH36 optimizes cross-protection against Leishmania amazonesis infection","volume":"8","author":"Alves-Silva","year":"2017","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/0974-777X.62883","article-title":"Treatment of visceral leishmaniasis","volume":"2","author":"Moore","year":"2010","journal-title":"J Glob Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"617521","DOI":"10.1155\/2010\/617521","article-title":"Drug resistance in visceral leishmaniasis","volume":"2010","author":"Maltezou","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0004297","DOI":"10.1371\/journal.pntd.0004297","article-title":"Immucillins ImmA and ImmH are effective and non-toxic in the treatment of experimental visceral leishmaniasis","volume":"9","author":"Freitas","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"B25","first-page":"119","article-title":"Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice","volume":"30","author":"Bradley","year":"1977","journal-title":"Clin Exp Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fimmu.2014.00189","article-title":"Cross-protective immunity to Leishmania amazonensis is mediated by CD4+ and CD8+ epitopes of Leishmania donovani nucleoside hydrolase terminal domains","volume":"5","author":"Nico","year":"2014","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1586\/14760584.7.6.833","article-title":"The FML-vaccine against canine visceral leishmaniasis: from the second generation to the synthetic vaccine","volume":"7","author":"Palatnik-de-Sousa","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"B28","doi-asserted-by":"publisher","first-page":"663","DOI":"10.4269\/ajtmh.2012.12-0180","article-title":"Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi","volume":"87","author":"Stober","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e24772","DOI":"10.1371\/journal.pone.0024772","article-title":"Destruction of lymphoid organ architecture and hepatitis caused by CD4+ T cells","volume":"6","author":"Matter","year":"2011","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e3213","DOI":"10.1371\/journal.pntd.0003213","article-title":"A randomised, double-blind, controlled efficacy trial of the LiESP\/QA-21 vaccine in na\u00efve dogs exposed to two Leishmania infantum transmission seasons","volume":"8","author":"Oliva","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5964","DOI":"10.1016\/j.vaccine.2009.07.069","article-title":"The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection","volume":"27","author":"Carcel\u00e9n","year":"2009","journal-title":"Vaccine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.mib.2012.05.002","article-title":"Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives","volume":"15","author":"Fernandes","year":"2012","journal-title":"Curr Opin Microbiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1016\/j.vaccine.2009.03.045","article-title":"Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas","volume":"27","author":"Palatnik-de-Sousa","year":"2009","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.vaccine.2005.11.061","article-title":"The FML-vaccine (Leishmune\u00ae) against canine visceral leishmaniasis: a transmission blocking vaccine","volume":"24","author":"Saraiva","year":"2006","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1016\/j.vaccine.2005.05.011","article-title":"Leishmune \u00ae vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs","volume":"23","author":"Nogueira","year":"2005","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0166-6851(02)00010-5","article-title":"Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis","volume":"120","author":"Santana","year":"2002","journal-title":"Mol Biochem Parasitol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin Transl Immunology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1622","DOI":"10.1371\/journal.pntd.0001622","article-title":"Improved canine and human visceral leishmaniasis immunodiagnosis using combinations of synthetic peptides in enzyme-linked immunosorbent assay","volume":"6","author":"Costa","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.micinf.2005.10.007","article-title":"Dendritic cells express CCR7 and migrate in response to CCL19 (MIP-3beta) after exposure to Helicobacter pylori","volume":"8","author":"Hansson","year":"2006","journal-title":"Microbes Infect"},{"key":"B41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1078\/0171-2985-00105","article-title":"Dendritic cell-based vaccination strategies: induction of protective immunity against leishmaniasis","volume":"204","author":"Moll","year":"2001","journal-title":"Immunobiology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0001-706X(93)90006-W","article-title":"Leishmania donovani surface glycoproteins GP36, is the major immunogen component of the fucose mannose ligand (FML)","volume":"53","author":"Palatnik de Sousa","year":"1993","journal-title":"Acta Trop"},{"key":"B43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0378-1119(01)00768-5","article-title":"A nonspecific nucleoside hydrolase from Leishmania donovani: implications for purine salvage by the parasite","volume":"280","author":"Cui","year":"2001","journal-title":"Gene"},{"key":"B44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1590\/S0037-86821996000200008","article-title":"The FML (fucose mannose ligand) of Leishmania donovani. a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar","volume":"29","author":"Palatnik de Sousa","year":"1996","journal-title":"Rev Soc Bras Med Trop"},{"key":"B45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.provac.2009.07.022","article-title":"The Nucleoside hydrolase DNA vaccine VR1012NH36 in prophylactic vaccination against mice tegumentar leishmaniaisis","volume":"1","author":"Souza","year":"2009","journal-title":"Procedia Vaccinol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/21645515.2016.1139254","article-title":"Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties","volume":"12","author":"Hudspeth","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B47","article-title":"Partial contribution of the B2 receptor of the kinin inflammation pathway in protection against murine visceral leishmaniasis by the C-terminal domain of nucleoside hydrolase vaccine","volume-title":"Abstract of the 5th Elsevier Vaccine and ISV Annual Global Congress","author":"Nico","year":"2011"},{"key":"B48","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2174\/0929867003374589","article-title":"Signal transduction pathways of G protein-coupled receptors and their cross-talk with receptor tyrosine kinases: lessons from bradykinin signaling","volume":"7","author":"Liebmann","year":"2000","journal-title":"Curr Med Chem"},{"key":"B49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1747-0285.2009.00825","article-title":"Advantages of a synthetic peptide immunogen over a protein immunogen in the development of an anti-pilus vaccine for Pseudomonas aeruginosa","volume":"74","author":"Kao","year":"2009","journal-title":"Chem Biol Drug Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1074\/jbc.M511571200","article-title":"Major histocompatibility complex and T cell interactions of a universal T-cell epitope from Plasmodium falciparum circumsporozoite protein","volume":"281","author":"Parra-L\u00f3pez","year":"2006","journal-title":"J Biol Chem"},{"key":"B51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4049\/jimmunol.151.1.489","article-title":"CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein","volume":"151","author":"Moreno","year":"1993","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1002\/eji.201242523","article-title":"Converse regulation of CCR7-driven human dendritic cell migration by prostaglandin E2 and liver X receptor activation","volume":"42","author":"Bruckner","year":"2012","journal-title":"Eur J Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"523","DOI":"10.5588\/ijtld.16.0371","article-title":"Type-1 polarised dendritic cells are a potent immunogen against Mycobacterium tuberculosis","volume":"21","author":"Satake","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1084\/jem.188.5.809","article-title":"Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable chlamydiae","volume":"188","author":"Su","year":"1998","journal-title":"J Exp Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0092-8674(01)00448-2","article-title":"Dendritic cells as vectors for therapy","volume":"106","author":"Banchereau","year":"2001","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2217\/fon.09.6","article-title":"Dendritic cell-based therapeutic cancer vaccines: what we have and what we need","volume":"5","author":"Kalinski","year":"2009","journal-title":"Future Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1080\/21645515.2015.1105415","article-title":"Dendritic cell targeted vaccines: recent progresses and challenges","volume":"12","author":"Chen","year":"2016","journal-title":"Hum Vaccin Immunother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00967\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T13:16:30Z","timestamp":1693660590000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00967\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,7]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2018.00967"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00967","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,7]]},"article-number":"967"}}